PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Atorvastatin

Drugs in development · updated 30 October 2026

Atorvastatin: clinical trials and development status

Other names and codes: Lipitor, Atorvaliq

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Atorvastatin is in 57 active clinical trials (recruiting or ongoing, phases I–III) for 64 diseases. The most advanced phase is III.

57Active trials
IIIMost advanced phase
64Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Atorvastatin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 64 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmIII4NCT05796973
Graves' ophthalmopathyIII3NCT05049603
InflammationII–III3NCT04147286
Ischemic strokeIII3NCT06358313
Prostatic NeoplasmsIII3NCT03819101
Pulmonary tuberculosisII–III3NCT04147286
TuberculosisII–III3NCT04147286
DyslipidemiaIII2NCT07045142
HypercholesterolemiaIII2NCT07474649
Ovarian neoplasmIII2NCT05796973
StrokeIII2NCT06358313
AtherosclerosisIII1NCT06930885
Carotid artery stenosisIII1NCT07586540
Chronic obstructive pulmonary diseaseII–III1NCT04147286
Coronary artery diseaseIII1NCT07474649
COVID-19III1NCT04904536
DementiaIII1NCT07012629
Kidney neoplasmIII1NCT05796973
Mucocutaneous Lymph Node SyndromeIII1NCT07530640
Neurologic ManifestationsIII1NCT04904536
Post-Acute COVID-19 SyndromeII–III1NCT06974084
Renal cell carcinomaIII1NCT05796973
SchizophreniaIII1NCT07045142
FibrosisII2NCT05028829
MigraineII2NCT06485336
Myelodysplastic SyndromesII2NCT05483010
Arrhythmias, CardiacII1NCT06922994
AscitesII1NCT06764966
Autosomal dominant polycystic kidneyII1NCT05870007
CardiotoxicityII1NCT05559164

Everything on Atorvastatin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch